OCS-Sparing Effect of Dupilumab for Severe Asthma Maintained

FRIDAY, July 22, 2022 -- Long-term treatment of severe asthma with dupilumab supports sustained reduction in oral corticosteroid (OCS) dosage and improvement in clinical end points for up to 96 weeks, according to a study published in the July issue...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news